IL272798B1 - Agonistic tnf receptor binding agents - Google Patents
Agonistic tnf receptor binding agentsInfo
- Publication number
- IL272798B1 IL272798B1 IL272798A IL27279820A IL272798B1 IL 272798 B1 IL272798 B1 IL 272798B1 IL 272798 A IL272798 A IL 272798A IL 27279820 A IL27279820 A IL 27279820A IL 272798 B1 IL272798 B1 IL 272798B1
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (10)
1./2 Claims 1. A bispecific antibody comprising at least two binding domains, wherein a first binding domain binds to a first receptor of the tumor necrosis factor (TNF) superfamily and a second binding domain binds to a second receptor of the TNF superfamily, wherein the first binding domain binding to CD40 comprises (a) the heavy chain complementarity determining region HCDR1 having the amino acid sequence of SEQ ID NO: 2323, the HCDR2 having the amino acid sequence of SEQ ID NO: 2324 and the HCDR3 having the amino acid sequence of SEQ ID NO: 2325, and the light chain complementarity determining region LCDR1 having the amino acid sequence of SEQ ID NO: 2326, the LCDR2 having the amino acid sequence of SEQ ID NO: 2327 and the LCDR3 having the amino acid sequence of SEQ ID NO: 2328; or (b) the heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2321 and the light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2322 and wherein the second binding domain binding to 4-1BB (CD137) comprises (a) the heavy chain complementarity determining region HCDR1 having the amino acid sequence of SEQ ID NO: 2297, the HCDR2 having the amino acid sequence of SEQ ID NO: 2298 and the HCDR3 having the amino acid sequence of SEQ ID NO: 2299, and the light chain complementarity determining region LCDR1 having the amino acid sequence of SEQ ID NO: 2300, the LCDR2 having the amino acid sequence of SEQ ID NO: 2301 and the LCDR3 having the amino acid sequence of SEQ ID NO: 2302; (b) the heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2241 and the light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2242; (c) the heavy chain complementarity determining region HCDR1 having the amino acid sequence of SEQ ID NO: 2255, the HCDR2 having the amino acid sequence of SEQ ID NO: 2256 and the HCDR3 having the amino acid sequence of SEQ ID NO: 2257, and 272798/2 the light chain complementarity determining region LCDR1 having the amino acid sequence of SEQ ID NO: 2258, the LCDR2 having the amino acid sequence of SEQ ID NO: 2259 and the LCDR3 having the amino acid sequence of SEQ ID NO: 2260; (d) the heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2227 and the light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2228; (e) the heavy chain complementarity determining region HCDR1 having the amino acid sequence of SEQ ID NO: 2315, the HCDR2 having the amino acid sequence of SEQ ID NO: 2316 and the HCDR3 having the amino acid sequence of SEQ ID NO: 2317, and the light chain complementarity determining region LCDR1 having the amino acid sequence of SEQ ID NO: 2318, the LCDR2 having the amino acid sequence of SEQ ID NO: 2319 and the LCDR3 having the amino acid sequence of SEQ ID NO: 2320; or (f) the heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2247 and the light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2248.
2. The bispecific antibody of claim 1, which is in the format of a full-length antibody.
3. The bispecific antibody according to claims 1 or 2, comprising one or more heavy chain constant domains of an immunoglobulin and/or light chain constant domains of an immunoglobulin.
4. A nucleic acid molecule encoding a bispecific antibody according to any one of claims to 3, wherein, preferably, the nucleic acid molecule is contained in a vector.
5. A cell comprising a nucleic acid molecule according to claim 4.
6. A pharmaceutical composition comprising, as an active agent, a bispecific antibody according to any one of claims 1 to 3, a nucleic acid molecule according to claim 4, or a cell according to claim 5. 272798/2
7. The pharmaceutical composition according to claim 6, further comprising a pharmaceutically acceptable carrier and/or excipient.
8. A kit comprising a bispecific antibody according to any one of claims 1 to 3, a nucleic acid molecule according to claim 4, a cell according to claim 5, or a pharmaceutical composition according to claim 6 or 7.
9. A bispecific antibody according to any one of claims 1 to 3, a nucleic acid molecule according to claim 4, a cell according to claim 5, or a pharmaceutical composition according to claim 6 or 7 for use as a medicament.
10. A bispecific antibody according to any one of claims 1 to 3, a nucleic acid molecule according to claim 4, a cell according to claim 5, or a pharmaceutical composition according to claim 6 or 7 for use in the treatment of a disease selected from the group consisting of cancer, infectious diseases, inflammatory diseases, metabolic diseases, autoimmune disorders and transplant rejections.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15050255 | 2015-01-08 | ||
| PCT/EP2016/050308 WO2016110584A1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL272798A IL272798A (en) | 2020-04-30 |
| IL272798B1 true IL272798B1 (en) | 2024-01-01 |
Family
ID=62452825
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272798A IL272798B1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
| IL309430A IL309430A (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
| IL252669A IL252669B (en) | 2015-01-08 | 2017-06-05 | Agonistic tnf receptor binding agents |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309430A IL309430A (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
| IL252669A IL252669B (en) | 2015-01-08 | 2017-06-05 | Agonistic tnf receptor binding agents |
Country Status (1)
| Country | Link |
|---|---|
| IL (3) | IL272798B1 (en) |
-
2016
- 2016-01-08 IL IL272798A patent/IL272798B1/en unknown
- 2016-01-08 IL IL309430A patent/IL309430A/en unknown
-
2017
- 2017-06-05 IL IL252669A patent/IL252669B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL272798A (en) | 2020-04-30 |
| IL309430A (en) | 2024-02-01 |
| IL252669B (en) | 2020-03-31 |
| IL252669A0 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191824T1 (en) | Agonistic tnf receptor binding agents | |
| RU2495050C2 (en) | Gm-csf receptor binder | |
| HRP20180269T1 (en) | Anti-cd40 antibodies, uses and methods | |
| HRP20170815T1 (en) | Fgfr1 agonists and methods of use | |
| RU2018145852A (en) | ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | |
| JP2020528768A5 (en) | ||
| JP2019501883A5 (en) | ||
| RU2018106364A (en) | ANTIBODIES AGAINST TFR RECEPTOR AND THEIR APPLICATION IN TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DISORDERS | |
| JP2015535828A5 (en) | ||
| HRP20201432T1 (en) | Il-17a binding agent and uses thereof | |
| JP2013121353A5 (en) | ||
| HRP20140108T1 (en) | Anti-sclerostin antibodies | |
| JP2013542194A5 (en) | ||
| RU2016138744A (en) | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS | |
| IL269270B (en) | Method and compositions for cellular immunotherapy | |
| CL2010001544A1 (en) | Humanized monoclonal antibody or binding fragment that binds and neutralizes the human vascular endothelial growth factor (hvegf); composition that includes it; nucleic acid coding; vector; host cell; its use to treat or prevent a disease mediated by vegf; and hybridoma. | |
| JP2016519650A5 (en) | ||
| JP2016520595A5 (en) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| HRP20191277T1 (en) | Anti-cd26 antibodies and uses thereof | |
| RU2019139093A (en) | PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | |
| RU2020127196A (en) | ANTIBODY AGAINST 4-1BB, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL APPLICATIONS | |
| JP2018522562A5 (en) | ||
| JP2020537520A5 (en) | ||
| RU2017134043A (en) | MODIFIED IGG ANTIBODIES THAT CONNECT TO THE BETA-1 TRANSFORMING GROWTH FACTOR WITH HIGH AFFICITY, ANIDITY AND SPECIFICITY |